J Korean Med Sci.  2023 Sep;38(36):e318. 10.3346/jkms.2023.38.e318.

Case 14: A 37-Year-Old Pregnant Woman With Thrombocytopenia

• Kim TY
• Lee J
• Jeon Y

• KMID: 2545789
• DOI: http://doi.org/10.3346/jkms.2023.38.e318

Figure

• 

  Fig. 1 FACS in PNH cells. FACS of red cells in CD55 and CD59 population of complete deficiency cells (type III) were 7.65%, and the population of partially deficient cells (type II) was 65.74% (A). FACSs of granulocytes in paroxysmal nocturnal hemoglobinuria using a combination of CD15 and CD24 were type III and type II, 88.46% and 3.04%, respectively (B).FACS = flow cytometric analysis, PE-A = phycoerythrin area, FITC-A = fluorescein isothiocyanate area, SSC-A = side scatter area, UL = upper left, LR = lower right.

Reference

1. Burrows RF, Kelton JG. Fetal thrombocytopenia and its relation to maternal thrombocytopenia. N Engl J Med. 1993; 329(20):1463–1466. PMID: 8413457.

2. Kelly RJ, Höchsmann B, Szer J, Kulasekararaj A, de Guibert S, Röth A, et al. Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2015; 373(11):1032–1039. PMID: 26352814.

3. Luzzatto L. PNH phenotypes and their genesis. Br J Haematol. 2020; 189(5):802–805. PMID: 32166737.

4. Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood. 2011; 117(25):6786–6792. PMID: 21460245.

5. Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, Pessoa V, Gualandro S, Füreder W, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019; 133(6):530–539. PMID: 30510080.

6. Inoue N, Izui-Sarumaru T, Murakami Y, Endo Y, Nishimura J, Kurokawa K, et al. Molecular basis of clonal expansion of hematopoiesis in 2 patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood. 2006; 108(13):4232–4236. PMID: 16940417.

7. DeZern AE, Jones RJ, Brodsky RA. Eculizumab bridging before bone marrow transplant for marrow failure disorders is safe and does not limit engraftment. Biol Blood Marrow Transplant. 2018; 24(12):e26–e30. PMID: 30055352.